Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus syrian hamster model

Veterinary Research

Volumn 42, Issue 1, 2011, Pages

  Nieto, Ana ^a   Domínguez Bernal, Gustavo ^b   Orden, José A ^b   De La Fuente, Ricardo ^b   Madrid Elena, Nadia ^c   Carrión, Javier ^b  

^a Anapath   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MESOCRICETUS AURATUS; MUS;

ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; HAMSTER; IMMUNOLOGY; LEISHMANIA; LIVER; MOUSE; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; SPLEEN; VISCERAL LEISHMANIASIS;

ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; LEISHMANIA; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; SPLEEN;

EID: 80052017606     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-42-39     Document Type: Review

References (71)

1. Advances in leishmaniasis. Murray HW, Berman JD, Davies CR, Saravia NG, Lancet 2005 366 1561 1577 10.1016/S0140-6736(05)67629-5 16257344 (Pubitemid 41540115)
2. Control of neglected tropical diseases. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, Savioli L, N Engl J Med 2007 357 1018 1027 10.1056/NEJMra064142 17804846 (Pubitemid 47367081)
3. Nuclear weapons and neglected diseases: the "ten-thousand-to-one gap". Hotez PJ, PLoS Negl Trop Dis 2010 4 680 10.1371/journal.pntd.0000680 20436916
4. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD, Lancet Infect Dis 2002 2 494 501 10.1016/S1473-3099(02)00347-X 12150849 (Pubitemid 34826855)
5. Leishmania spp infection in injecting drug users. Pineda JA, Martin-Sanchez J, Macias J, Morillas F, Lancet 2002 360 950 951 10.1016/S0140-6736(02)11056-7 12354499 (Pubitemid 35283848)
6. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Dujardin JC, Campino L, Canavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M, Emerg Infect Dis 2008 14 1013 1018 10.3201/eid1407. 071589 18598618 (Pubitemid 351920428)
7. Experimental canine leishmaniasis: Clinical, parasitological and serological follow-up. Maia C, Nunes M, Cristovao J, Campino L, Acta Trop 2010 116 193 199 10.1016/j.actatropica.2010.08.001 20696122
8. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M, Mortarino M, Pietrobelli M, Gradoni L, Trop Med Int Health 2008 13 256 264 10.1111/j.1365-3156.2007.01998.x 18304273 (Pubitemid 351316978)
9. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Bogdan C, Schonian G, Banuls AL, Hide M, Pratlong F, Lorenz E, Rollinghoff M, Mertens R, Clin Infect Dis 2001 32 302 306 10.1086/318476 11170923 (Pubitemid 32524804)
10. Immunopathogenesis of infection with the visceralizing Leishmania species. Wilson ME, Jeronimo SM, Pearson RD, Microb Pathog 2005 38 147 160 10.1016/j.micpath.2004.11.002 15797810 (Pubitemid 40417730)
11. Clinical spectrum of Leishmaniasis. Pearson RD, Sousa AQ, Clin Infect Dis 1996 22 1 13 10.1093/clinids/22.Supplement-1.S1 8824958 (Pubitemid 26022004)
12. Immune complex glomerulonephritis in experimental kala-azar. Sartori A, De Oliveira AV, Roque-Barreira MC, Rossi MA, Campos-Neto A, Parasite Immunol 1987 9 93 103 10.1111/j.1365-3024.1987.tb00491.x 2951644 (Pubitemid 17026572)
13. Identification of immune complex antigens in sera of Indian kala-azar patients. Sanyal T, Ghosh DK, Sarkar D, Indian J Exp Biol 1991 29 411 415 1916938
14. Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. Croft SL, Vivas L, Brooker S, East Mediterr Health J 2003 9 518 533 15748049 (Pubitemid 40485290)
15. Leishmaniasis as an emerging infection. Choi CM, Lerner EA, J Investig Dermatol Symp Proc 2001 6 175 182 10.1046/j.0022-202x.2001.00038.x 11924824 (Pubitemid 33758571)
16. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG Jr, de Oliveira SM, Palatnik-de-Sousa CB, Vaccine 2006 24 2423 2431 10.1016/j.vaccine.2005.11.061 16386824 (Pubitemid 43290426)
17. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil. Parra LE, Borja-Cabrera GP, Santos FN, Souza LO, Palatnik-de-Sousa CB, Menz I, Vaccine 2007 25 2180 2186 10.1016/j.vaccine.2006. 11.057 17239495 (Pubitemid 46242143)
18. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Dantas-Torres F, Vet Parasitol 2006 141 1 8 10.1016/j.vetpar.2006.05.001 16750885 (Pubitemid 44363138)
19. Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis. de Lima VM, Ikeda FA, Rossi CN, Feitosa MM, Vasconcelos RO, Nunes CM, Goto H, Vet Immunol Immunopathol 2010 135 296 302 10.1016/j.vetimm.2009.12.008 20132994
20. Leishmania species: models of intracellular parasitism. Alexander J, Satoskar AR, Russell DG, J Cell Sci 1999 112 Pt 18 2993 3002 10462516 (Pubitemid 29465717)
21. Leishmania spp.: on the interactions they establish with antigen-presenting cells of their mammalian hosts. Antoine JC, Prina E, Courret N, Lang T, Adv Parasitol 2004 58 1 68 10.1016/S0065-308X(04)58001-6 15603761 (Pubitemid 39643142)
22. Leishmaniasis: current status of vaccine development. Handman E, Clin Microbiol Rev 2001 14 229 243 10.1128/CMR.14.2.229-243.2001 11292637 (Pubitemid 32294669)
23. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Hommel M, Jaffe CL, Travi B, Milon G, Ann Trop Med Parasitol 1995 89 Suppl 1 55 73 8745928 (Pubitemid 26030069)
24. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS, Teale JM, Exp Parasitol 2001 99 17 25 10.1006/expr.2001.4640 11708830 (Pubitemid 33116623)
25. Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Requena JM, Soto M, Doria MD, Alonso C, Vet Immunol Immunopathol 2000 76 269 281 10.1016/S0165-2427(00)00221-X 11044559
26. Immunohistological features of visceral leishmaniasis in BALB/c mice. Carrion J, Nieto A, Iborra S, Iniesta V, Soto M, Folgueira C, Abanades DR, Requena JM, Alonso C, Parasite Immunol 2006 28 173 183 10.1111/j.1365-3024.2006. 00817.x 16629702
27. Reduced hamster usage and stress in propagating Leishmania chagasi promastigotes using cryopreservation and saphenous vein inoculation. Lei SM, Ramer-Tait AE, Dahlin-Laborde RR, Mullin K, Beetham JK, J Parasitol 2010 96 103 108 10.1645/GE-2192.1 19835434
28. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. Melby PC, Chandrasekar B, Zhao W, Coe JE, J Immunol 2001 166 1912 1920 11160239 (Pubitemid 32114678)
29. Setting new immunobiological parameters in the hamster model of visceral leishmaniasis for in vivo testing of antileishmanial compounds. Dea-Ayuela MA, Rama-Iniguez S, Alunda JM, Bolas-Fernandez F, Vet Res Commun 2007 31 703 717 10.1007/s11259-007-0040-5 17237986 (Pubitemid 46951269)
30. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Goto H, Prianti MG, Rev Inst Med Trop Sao Paulo 2009 51 241 246 19893975
31. Immunity and immunosuppression in experimental visceral leishmaniasis. Goto H, Lindoso JA, Braz J Med Biol Res 2004 37 615 623 10.1590/S0100- 879X2004000400020 15064826 (Pubitemid 38618559)
32. Early histopathology of experimental infection with Leishmania donovani in hamsters. Wilson ME, Innes DJ, Sousa AD, Pearson RD, J Parasitol 1987 73 55 63 10.2307/3282344 3572666 (Pubitemid 17119866)
33. Immunological and histopathological studies in a rodent model infected with Leishmania infantum promastigotes or amastigotes. Rica-Capela MJ, Cortes S, Leandro C, Peleteiro MC, Santos-Gomes G, Campino L, Parasitol Res 2003 89 163 169 12541057 (Pubitemid 36216539)
34. Immune complex glomerulonephritis in experimental kala-azar. II: Detection and characterization of parasite antigens and antibodies eluted from kidneys of Leishmania donovani-infected hamsters. Sartori A, Roque-Barreira MC, Coe J, Campos-Neto A, Clin Exp Immunol 1992 87 386 392 10.1111/j.1365-2249.1992. tb03007.x 1544224
35. Histopathologic analysis of hamster hepatocytes submitted to experimental infection with Leishmania donovani. Vianna VL, Takiya CM, de Brito-Gitirana L, Parasitol Res 2002 88 829 836 12172815 (Pubitemid 35005846)
36. Syrian hamster infected with Leishmania infantum: a new experimental model for inflammatory myopathies. Paciello O, Wojcik S, Gradoni L, Oliva G, Trapani F, Iovane V, Politano L, Papparella S, Muscle Nerve 2010 41 355 361 10.1002/mus.21502 19813199
37. Canine inflammatory myopathy associated with Leishmania Infantum infection. Paciello O, Oliva G, Gradoni L, Manna L, Manzillo VF, Wojcik S, Trapani F, Papparella S, Neuromuscul Disord 2009 19 124 130 10.1016/j.nmd.2008. 10.013 19084398
38. Slc11a1 limits intracellular growth of Salmonella enterica sv. Typhimurium by promoting macrophage immune effector functions and impairing bacterial iron acquisition. Nairz M, Fritsche G, Crouch ML, Barton HC, Fang FC, Weiss G, Cell Microbiol 2009 11 1365 1381 10.1111/j.1462-5822.2009.01337.x 19500110
39. Genetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infection. Roupie V, Rosseels V, Piersoel V, Zinniel DK, Barletta RG, Huygen K, Infect Immun 2008 76 2099 2105 10.1128/IAI.01137-07 18285491 (Pubitemid 351656143)
40. Intracellular Leishmania: your iron or mine? Marquis JF, Gros P, Trends Microbiol 2007 15 93 95 10.1016/j.tim.2007.01.001 17257847 (Pubitemid 46356977)
41. Iron acquisition within host cells and the pathogenicity of Leishmania. Huynh C, Andrews NW, Cell Microbiol 2008 10 293 300 10.1111/j.1462-5822.2007. 01095.x 18070118
42. The immunopathology of experimental visceral leishmaniasis. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR, Immunol Rev 2004 201 239 253 10.1111/j.0105-2896.2004.00188.x 15361245 (Pubitemid 39318456)
43. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Lipoldova M, Demant P, Nat Rev Genet 2006 7 294 305 10.1038/nrg1832 16543933
44. Balancing immunity and pathology in visceral leishmaniasis. Stanley AC, Engwerda CR, Immunol Cell Biol 2007 85 138 147 10.1038/sj.icb7100011 17146466 (Pubitemid 46398719)
45. Parasites and individual major histocompatibility complex diversity - an optimal choice? Wegner KM, Kalbe M, Schaschl H, Reusch TB, Microbes Infect 2004 6 1110 1116 10.1016/j.micinf.2004.05.025 15380781 (Pubitemid 39236450)
46. Participation of natural killer cells in the recovery of mice from visceral leishmaniasis. Kirkpatrick CE, Farrell JP, Warner JF, Denner G, Cell Immunol 1985 92 163 171 10.1016/0008-8749(85)90074-7 4075411 (Pubitemid 15072857)
47. Variation in susceptibility of mouse strains to Leishmania donovani infection. Bradley DJ, Kirkley J, Trans R Soc Trop Med Hyg 1972 66 527 528 10.1016/0035-9203(72)90083-1 5071050
48. Organ-specific immune responses associated with infectious disease. Engwerda CR, Kaye PM, Immunol Today 2000 21 73 78 10.1016/S0167-5699(99)01549-2 10652464 (Pubitemid 30069619)
49. NK cell activation in visceral leishmaniasis requires TLR9, myeloid DCs, and IL-12, but is independent of plasmacytoid DCs. Schleicher U, Liese J, Knippertz I, Kurzmann C, Hesse A, Heit A, Fischer JA, Weiss S, Kalinke U, Kunz S, Bogdan C, J Exp Med 2007 204 893 906 10.1084/jem.20061293 17389237 (Pubitemid 46631617)
50. Modulation of dendritic cell function by Leishmania parasites. Soong L, J Immunol 2008 180 4355 4360 18354154
51. Acquired resistance and granuloma formation in experimental visceral leishmaniasis. Differential T cell and lymphokine roles in initial versus established immunity. Murray HW, Squires KE, Miralles CD, Stoeckle MY, Granger AM, Granelli-Piperno A, Bogdan C, J Immunol 1992 148 1858 1863 1541824
52. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. Murray HW, Nathan CF, J Exp Med 1999 189 741 746 10.1084/jem.189.4.741 9989990 (Pubitemid 29193376)
53. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. Squires KE, Schreiber RD, McElrath MJ, Rubin BY, Anderson SL, Murray HW, J Immunol 1989 143 4244 4249 2512353 (Pubitemid 20012622)
54. Tissue granuloma structure-function in experimental visceral leishmaniasis. Murray HW, Int J Exp Pathol 2001 82 249 267 10.1046/j.1365-2613. 2001.00199.x 11703536 (Pubitemid 34225158)
55. Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Hernandez-Pando R, Bornstein QL, Aguilar Leon D, Orozco EH, Madrigal VK, Martinez Cordero E, Immunology 2000 100 352 358 10.1046/j.1365-2567.2000.00025.x 10929057 (Pubitemid 30449949)
56. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Stager S, Alexander J, Carter KC, Brombacher F, Kaye PM, Infect Immun 2003 71 4804 4807 10.1128/IAI.71.8.4804-4807.2003 12874364 (Pubitemid 36919951)
57. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL, Nature 2002 420 502 507 10.1038/nature01152 12466842 (Pubitemid 35477041)
58. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, McFarlane E, Vaccine 2007 25 4502 4509 10.1016/j.vaccine.2007.03.014 17418459 (Pubitemid 46678561)
59. Structure and function of the spleen. Mebius RE, Kraal G, Nat Rev Immunol 2005 5 606 616 10.1038/nri1669 16056254 (Pubitemid 41113192)
60. Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. Ato M, Maroof A, Zubairi S, Nakano H, Kakiuchi T, Kaye PM, J Immunol 2006 176 5486 5493 16622017
61. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Gorak PM, Engwerda CR, Kaye PM, Eur J Immunol 1998 28 687 695 10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0. CO;2-N 9521079 (Pubitemid 28101746)
62. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Engwerda CR, Ato M, Kaye PM, Trends Parasitol 2004 20 524 530 10.1016/j.pt.2004.08.009 15471704 (Pubitemid 39313091)
63. Destruction of follicular dendritic cells during chronic visceral leishmaniasis. Smelt SC, Engwerda CR, McCrossen M, Kaye PM, J Immunol 1997 158 3813 3821 9103448 (Pubitemid 127488739)
64. Immunosuppression in hamsters with progressive visceral leishmaniasis: an evaluation of the role of nitric oxide toward impairment of the lymphoproliferative response. Dasgupta S, Mookerjee A, Chowdhury SK, Ghose AC, Parasitol Res 1999 85 594 596 10.1007/s004360050600 10382610 (Pubitemid 29249883)
65. Immunosuppression in hamsters with progressive visceral leishmaniasis is associated with an impairment of protein kinase C activity in their lymphocytes that can be partially reversed by okadaic acid or anti-transforming growth factor beta antibody. Mookerjee A, Sen PC, Ghose AC, Infect Immun 2003 71 2439 2446 10.1128/IAI.71.5.2439-2446.2003 12704114 (Pubitemid 36519855)
66. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Ahmed S, Colmenares M, Soong L, Goldsmith-Pestana K, Munstermann L, Molina R, McMahon-Pratt D, Infect Immun 2003 71 401 410 10.1128/IAI.71.1.401-410.2003 12496190 (Pubitemid 36026044)
67. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Carrion J, Folgueira C, Alonso C, Vaccine 2008 26 2537 2544 10.1016/j.vaccine.2008.03.003 18400342
68. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. Ravindran R, Bhowmick S, Das A, Ali N, BMC Microbiol 2010 10 181 20576102
69. Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Mukherjee P, Ghosh AK, Ghose AC, Immunol Lett 2003 86 131 138 10.1016/S0165-2478(03)00021-X 12644314 (Pubitemid 36324273)
70. Defect in the tissue cellular immune response: experimental visceral leishmaniasis in euthymic C57BL/6 ep/ep mice. Squires KE, Kirsch M, Silverstein SC, Acosta A, McElrath MJ, Murray HW, Infect Immun 1990 58 3893 3898 2123825
71. Leishmania infantum: mixed T-helper-1/T-helper-2 immune response in experimentally infected BALB/c mice. Rolao N, Cortes S, Gomes-Pereira S, Campino L, Exp Parasitol 2007 115 270 276 10.1016/j.exppara.2006.09.013 17087930 (Pubitemid 44828068)